Comprehensive review of membranoproliferative glomerulonephritis: spotlighting the latest advances in revised classification and treatment
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Membranoproliferative glomerulonephritis (MPGN) is a complex group of renal diseases characterized by a specific pattern of glomerular injury that includes thickening of the capillary wall and mesangial expansion, leading to a heterogeneous group of conditions. This review article offers a comprehensive overview of MPGN, its new classification, pathophysiology, diagnostic evaluation, and management options.
Abstract
Membranoproliferative glomerulonephritis (MPGN) is a complex group of renal diseases characterized by a specific pattern of glomerular injury that includes thickening of the capillary wall and mesangial expansion, leading to a heterogeneous group of conditions. This review article offers a comprehensive overview of MPGN, its new classification, pathophysiology, diagnostic evaluation, and management options.
참고문헌 (26)
- Sethi S, "Membranoproliferative glomerulonephritis : a new look at an old entity", N Engl J Med, 366, pp.1119~1131 (2012)
- Kidney Disease : Improving Global Outcomes(KDIGO)Glomerular Diseases Work Group, "KDIGO 2021 Clinical practice guideline for the management of glomerular diseases", Kidney Int, 100(4S), pp.S1~276 (2021)
- Fogo AB, "AJKD atlas of renal pathology : membranoproliferative glomerulonephritis", Am J Kidney Dis, 66, pp.e19~20 (2015)
- Sethi S, "Membranoproliferative glomerulonephritis : pathogenetic heterogeneity and proposal for a new classification", Semin Nephrol, 31, pp.341~348 (2011)
- Xu L, "Characteristics and outcomes of glomerulonephritis with membranoproliferative pattern in children", Transl Pediatr, 10, pp.2985~2996 (2021)
- Servais A, "Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies", Kidney Int, 82, pp.454~464 (2012)
- Ruggenenti P, "C5 convertase blockade in membranoproliferative glomerulonephritis : a single-arm clinical trial", Am J Kidney Dis, 74, pp.224~238 (2019)
- Angioi A, "Diagnosis of complement alternative pathway disorders", Kidney Int, 89, pp.278~288 (2016)
- Leung N, "The evaluation of monoclonal gammopathy of renal significance : a consensus report of the International Kidney and Monoclonal Gammopathy Research Group", Nat Rev Nephrol, 15, pp.45~59 (2019)
- Pickering MC, "C3 glomerulopathy : consensus report", Kidney Int, 84, pp.1079~1089 (2013)
- Servais A, "Primary glomerulonephritis with isolated C3deposits : a new entity which shares common genetic risk factors with haemolytic uraemic syndrome", J Med Genet, 44, pp.193~199 (2007)
- Bomback AS, "C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy", Kidney Int, 93, pp.977~985 (2018)
- Ravindran A, "C3 glomerulopathy : ten years’ experience at Mayo Clinic", Mayo Clin Proc, 93, pp.991~1008 (2018)
- Sethi S, "C4 glomerulopathy : a disease entity associated with C4d deposition", Am J Kidney Dis, 67, pp.949~953 (2016)
- Mastrangelo A, "Clinical and pathophysiological insights into immunological mediated glomerular diseases in childhood", Front Pediatr, 8, pp.205~ (2020)
- Cook HT, "Histopathology of MPGN and C3 glomerulopathies", Nat Rev Nephrol, 11, pp.14~22 (2015)
- Tarshish P, "Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone : a report of the International Study of Kidney Disease in Children", Pediatr Nephrol, 6, pp.123~130 (1992)
- Kirpalani A, "Long-term outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis in children", Kidney Int Rep, 5, pp.2313~2324 (2020)
- Fervenza FC, "Idiopathic membranoproliferative glomerulonephritis: does it exist?", Nephrol Dial Transplant, 27, pp.4288~4294 (2012)
- Goodship TH, "Atypical hemolytic uremic syndrome and C3glomerulopathy : conclusions from a"Kidney Disease : Improving Global Outcomes"(KDIGO)Controversies Conference", Kidney Int, 91, pp.539~551 (2017)
- Medjeral-Thomas NR, "C3 glomerulopathy : clinicopathologic features and predictors of outcome", Clin J Am Soc Nephrol, 9, pp.46~53 (2014)
- Rabasco C, "Effectiveness of mycophenolate mofetil in C3 glomerulonephritis", Kidney Int, 88, pp.1153~1160 (2015)
- Avasare RS, "Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy : a case series", Clin J Am Soc Nephrol, 13, pp.406~413 (2018)
- Le Quintrec M, "Patterns of clinical response to eculizumab in patients with C3 glomerulopathy", Am J Kidney Dis, 72, pp.84~92 (2018)
- Nakagawa N, "Clinical features and pathogenesis of membranoproliferative glomerulonephritis : a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015", Clin Exp Nephrol, 22, pp.797~807 (2018)
- Lee H, "Mortality and renal outcome of primary glomerulonephritis in Korea: observation in 1,943 biopsied cases", Am J Nephrol, 37, pp.74~83 (2013)
